Finasteride Global Regulatory Status

FDA Approval History: From Proscar to Propecia

Finasteride entered the U.S. market on June 19, 1992, when the FDA approved Merck's 5 mg tablet (Proscar) for symptomatic BPH in men with an enlarged prostate. The approval rested on three key Phase III trials enrolling a combined 1,645 men, which demonstrated a roughly 20% reduction in prostate volume and significant improvement in urinary symptom scores over 12 months compared with placebo (Drugs@FDA: Proscar).

Five years later, Merck secured a second indication. On December 19, 1997, the FDA approved finasteride 1 mg (Propecia) for the treatment of male pattern hair loss (androgenetic alopecia) in men only. The registration program included two randomized, placebo-controlled trials (N=1,553 combined) that ran for two years. At 12 months, 48% of men on finasteride 1 mg had increased hair count by manual target-area assessment versus 7% on placebo [1]. Kaufman et al. published the key efficacy data showing that finasteride 1 mg increased hair count by a mean of 107 hairs in a 1-inch target area at one year (Kaufman et al., 1998).

The drug is not approved for use in women. The FDA label carries a specific contraindication in women of childbearing potential due to the risk of hypospadias and ambiguous genitalia in male fetuses exposed in utero (FDA Propecia Label).

European and U.K. Regulatory Pathway

Finasteride did not go through the EMA's centralized procedure. Instead, it received marketing authorizations via national mutual-recognition procedures across EU member states during the mid-to-late 1990s. The 5 mg formulation for BPH was approved first, followed by the 1 mg formulation for androgenetic alopecia. Each national medicines agency (e.g., BfArM in Germany, ANSM in France, MHRA in the U.K.) issued its own marketing authorization, though the Summary of Product Characteristics (SmPC) is broadly harmonized through periodic EU referral procedures.

In 2018, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) completed a review and mandated updated warnings across all EU member states. The revised SmPC now states that sexual dysfunction, including erectile dysfunction, decreased libido, and ejaculation disorders, "may persist after discontinuation of treatment" (EMA PRAC Recommendation, 2018). The MHRA retained finasteride's prescription-only status following Brexit and adopted identical warning language in the U.K. SmPC.

Regulatory Status in Asia-Pacific and Other Markets

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved finasteride 1 mg (marketed as Propecia by MSD K.K.) in 2005 for male androgenetic alopecia. Japan was notably later than Western markets. The 5 mg BPH indication is also available under the Proscar brand. Australia's Therapeutic Goods Administration (TGA) approved both doses in the 1990s; finasteride 1 mg is Schedule 4 (prescription-only) in Australia.

Canada's Health Canada authorized Proscar in 1992 and Propecia in 1998, tracking closely with FDA timelines. In 2015, Health Canada required a label update adding "suicidal ideation" to the adverse reaction section following a safety signal review. Brazil's ANVISA, South Korea's MFDS, and India's CDSCO have all issued approvals, and generic finasteride is widely available in these markets at both dose levels.

No major regulatory authority has approved finasteride for use in women for any indication. This is a point of consistency across the FDA, EMA, PMDA, TGA, and Health Canada.

Label Evolution: Sexual Adverse Events

The finasteride label has undergone more post-market revisions than most drugs in the 5-alpha reductase inhibitor class. The original 1992 Proscar label listed decreased libido (6.4% vs. 3.4% placebo), impotence (8.1% vs. 3.7%), and decreased volume of ejaculate as adverse reactions based on the key BPH trials.

A turning point came in April 2011. The FDA required Merck to revise the Propecia label to include reports that sexual side effects such as erectile dysfunction, decreased libido, and ejaculation disorder "continued after discontinuation of the drug" (FDA Safety Communication, April 2012). This was a significant departure from the original trial data, which had suggested side effects resolved after stopping the medication.

The Kaufman et al. key trial reported that drug-related sexual adverse events occurred in 3.8% of finasteride-treated men versus 2.1% on placebo at 12 months, and resolved in all men who discontinued [1]. Post-marketing surveillance told a different story. The FDA's Adverse Event Reporting System (FAERS) accumulated thousands of reports describing persistent sexual dysfunction lasting months to years after finasteride discontinuation, a constellation of symptoms some researchers have termed "post-finasteride syndrome" (PFS).

A 2017 retrospective cohort study using the U.S. Military Health System database (N=12,346 finasteride users) published in PeerJ found that men under 42 years who used finasteride for more than 205 days had a 4.9-fold higher risk of persistent erectile dysfunction compared with non-users (HR 4.92, 95% CI 2.18-11.11) (Kiguradze et al., 2017).

Prostate Cancer Risk: The PCPT Controversy

The Prostate Cancer Prevention Trial (PCPT, N=18,882) randomized men aged 55 and older to finasteride 5 mg or placebo for seven years. Results published in the New England Journal of Medicine in 2003 showed a 24.8% relative reduction in prostate cancer prevalence (18.4% finasteride vs. 24.4% placebo, P<0.001). But the trial also found a statistically significant increase in high-grade tumors (Gleason 7-10): 6.4% in the finasteride arm vs. 5.1% in the placebo arm (Thompson et al., 2003).

This finding created a regulatory impasse. In December 2010, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 14-2 against approving a prostate cancer prevention indication for finasteride. The committee cited the high-grade cancer signal and determined the benefit-risk ratio was unfavorable for chemoprevention in the general population.

In June 2011, the FDA mandated a label change for both Proscar and Propecia, adding a warning about "an increased risk of high-grade prostate cancer" based on the PCPT data (FDA Label Revision, 2011). Long-term follow-up of the PCPT cohort at 18 years, published in 2013, showed no significant difference in overall survival between the finasteride and placebo groups (78.0% vs. 78.2%), partially mitigating the initial concern (Thompson et al., 2013).

Depression and Suicidality Warnings

In December 2022, the FDA required another label revision. New warnings for depression and suicidal ideation were added to the prescribing information for all finasteride products, based on a cumulative review of post-marketing reports and published literature (FDA Safety Label Update, 2022).

The evidence base for this revision included a 2020 pharmacovigilance analysis by Nguyen et al. using FAERS data that identified a disproportionate reporting ratio for suicidality among finasteride users compared with other drugs in the database (Nguyen et al., 2021). A Swedish nationwide cohort study (N=170,000+ men) published in BMJ in 2024 found a modest but statistically significant association between finasteride use and incident depression (HR 1.23, 95% CI 1.14-1.33), with risk concentrated in the first 18 months of use (Brännström et al., 2024).

Health Canada added suicidal ideation to the Canadian Product Monograph in 2015, seven years before the FDA followed. The EMA's PRAC recommended updating the SmPC with information on depressed mood and suicidal thoughts in 2018. Regulatory timelines for psychiatric safety signals have differed by years across agencies, reflecting divergent pharmacovigilance thresholds.

Generic Availability and Patent Expiration

Merck's composition-of-matter patent on finasteride expired in June 2006, opening the door for generic 5 mg tablets in the U.S. The 1 mg hair-loss formulation followed when Propecia's use patent expired in November 2013. As of 2026, the FDA's Orange Book lists more than 20 approved ANDA holders for finasteride tablets across both strengths.

Generic finasteride 1 mg costs roughly $3-15 per month in the U.S. retail pharmacy setting, compared with $60+ for branded Propecia (where still available). The price collapse after generic entry made finasteride one of the most accessible prescription hair-loss treatments globally. In the U.K., finasteride 1 mg moved from prescription-only to pharmacy-supply (P medicine) for hair loss via a reclassification pilot in select regions, though this remains limited.

FDA Sentinel and Active Post-Market Surveillance

The FDA has included finasteride in its Sentinel System active surveillance program, a distributed data network querying electronic health records and claims databases across more than 100 million patient lives. Sentinel assessments have focused on two signals: persistent sexual dysfunction and suicidality.

A 2018 Sentinel-commissioned study examined new-user cohorts of men prescribed finasteride (any dose) and found that the incidence of erectile dysfunction diagnoses was 15.6 per 1,000 person-years in finasteride users vs. 9.4 per 1,000 person-years in matched non-users. The American Urological Association (AUA) guidelines for BPH management acknowledge the sexual side effect profile and recommend discussing potential persistent effects before starting therapy (AUA BPH Guideline, 2021).

The Endocrine Society's 2019 clinical practice guideline on androgen therapy references finasteride in the context of 5-alpha reductase inhibition and counsels clinicians to "inform patients about the possibility of sexual side effects that may not resolve with drug discontinuation" (Bhasin et al., Endocrine Society, 2018).

Current Prescribing Requirements Across Markets

Finasteride remains prescription-only in all major regulatory jurisdictions. No country has moved finasteride to full over-the-counter status. The prescribing requirements vary by market:

In the United States, any licensed prescriber (physician, nurse practitioner, physician assistant) can write a finasteride prescription. No specialist referral is required. Telehealth prescribing of finasteride 1 mg for hair loss has become common through platforms like HealthRX, Hims, and Keeps.

In Japan, finasteride 1 mg for hair loss must be prescribed by a physician after an in-person consultation. Telehealth prescribing for finasteride expanded during the COVID-19 pandemic through temporary regulatory flexibilities, some of which have been made permanent.

In Australia, finasteride is a Schedule 4 prescription medicine. The TGA requires dispensing through a registered pharmacy with a valid prescription. In 2023, the TGA evaluated and rejected a proposal to downschedule finasteride 1 mg to Schedule 3 (pharmacist-only), citing ongoing safety signal monitoring.

Across all markets, prescribers are expected to counsel patients on the potential for persistent sexual side effects, the 2022 psychiatric warnings, and the need for ongoing monitoring. Women of childbearing age should not handle crushed or broken finasteride tablets due to the teratogenicity risk via dermal absorption.